Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)

National Institutes of Health

The purpose of this notice of funding opportunity (NOFO) is to support preclinical HIV/AIDS research using NHP models performed by Early Stage Investigators (ESIs) who are within 10 years of their terminal degree or completion of their residency training but who have at least two years of postdoctoral experience. The goal of this support is to help advance HIV/AIDS researchers using NHP models in preclinical research by providing a degree of independence for these ESIs to develop new research directions and to position these researchers to be competitive for new research funding (e.g., R01). Proposed projects must use NHPs as preclinical models for HIV/AIDS research. This funding initiative encompasses all priorities of the fiscal year (FY) 2021-2025 NIH Strategic Plan for HIV and HIV-Related Research ( https://www.oar.nih.gov/hiv-policy-and-research/strategic-plan ): reduce the incidence of HIV; develop next-generation HIV therapies; conduct research toward HIV cure; address HIV-associated comorbidities, coinfections, and complications; and advance cross-cutting areas of research.

AIDS Application Due Date(s): Jan. 7, May 7, Sep 7

PAR-25-165 Expiration Date September 08, 2025

Specialties

Infectious Diseases

Eligibility Requirements

Applicants for this award must meet the NIH definition of an Early Stage Investigator . Additional requirements for eligibility are that the applicant must have a research or health-professional doctoral degree, must have completed at least two years of postdoctoral training or equivalent, must be within 10 years of their terminal degree or completion of residency, and must be an Assistant Professor, Assistant Scientist, Research Assistant Professor, or equivalent.

Professors, Associate Professors or equivalent are not eligible.

The candidate should have an appointment at an institution that includes an NHP facility, such as a National Primate Research Center or similar, which can provide NHPs, core facilities and intellectual resources for using NHPs in HIV/AIDS research. If exceptionally well justified, the candidate may have a primary appointment at an institution distinct from those which houses NHP-related facilities and infrastructure. However, all work directly related to animals must be performed at the institution that houses the NHP-related facilities and related infrastructure.

Eligible Countries:

United States

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Sponsor Type:

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity